1. Pink Sheet
  2. >>Geography

SIFI Among EU Fast-Track Hopefuls With ‘World’s First’ Drug For Parasitic Eye Infection

EU Filing For Akantior Planned In Q2

 
• By Neena Brizmohun

SIFI is set to learn whether the European Medicines Agency will agree that its planned EU marketing application for Akantior merits an accelerated assessment, as is Janssen for its combination treatment for prostate cancer.

The European Medicines Agency is due to decide this week whether to fast track its assessment of the planned EU marketing authorization applications for two investigational products – Akantior (polyhexanide), for treating acanthamoeba keratitis, and Zejula (niraparib) plus Zytiga (abiraterone acetate), for prostate cancer.

Akantior is being developed by Italian company SIFI, which believes its eye drop-based product could become the world’s first...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

New EU Filings

 
• By Neena Brizmohun

Linerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.